Arlene Forastiere Everett Vokes Michael Skinner Mark Chambers Larynx Cancer: Concurrent Chemoradiotherapy: Best for Larynx Preservation REFERENCE: Abstract 5517 Arlene Forastiere, Sidney Kimmel Compre

Arlene Forastiere

Everett Vokes

Michael Skinner

Mark Chambers
Larynx Cancer: Concurrent Chemoradiotherapy: Best for Larynx Preservation
REFERENCE: Abstract 5517
Arlene Forastiere, Sidney Kimmel Comprehensive Cancer Center, Baltimore
In patients with larynx cancer, Arlene Forastiere of the Sidney Kimmel Comprehensive Cancer Center in Baltimore says that the best way to treat the cancer and preserve the larynx is to give radiation and chemotherapy concurrently – and not to use “induction” chemotherapy. Everett Vokes from the University of Chicago adds his comments and recommendations.
ZD6474: New Treatment Avenue in Thyroid Cancer?
REFERENCE: Abstract 5533
Michael Skinner, Duke University Medical Center, Durham
Patients with hereditary metastatic medullary thyroid cancer could have a new treatment on the horizon, in the form of ZD6474, an inhibitor of the RET receptor. Michael Skinner from Duke University Medical Center in Durham had the data at ASCO.
New Remedy for Radiation Induced Oral Mucositis
REFERENCE: Abstract 5523
Mark Chambers, MD Anderson Cancer Center, Houston
Patients with oral mucositis induced by radiation for head and neck cancer may soon be able to turn to a new drug called RK-0202. Mark Chambers of the MD Anderson Cancer Center in Houston told ASCO delegates about his new study.
[audio:https://www.audiomedica.com/podcasting/asco/06.06.15_ASCO_podcast.mp3]
Related Episodes

Jefferson DeKloe BSc: Big US Study Confirms Benefit of HPV Vaccination for Boys as Well as Girls
The cancer prevention benefit of vaccination against the human papilloma virus cancer prevent are slowly accruing thanks to European, American and other population-based studies. I’m Peter Goodwin wi

Luis Paz-Ares MD PhD: Longer Survival Among Patients with Extensive Stage Small Cell Lung Cancer Treated with Lurbinectedin Maintenance —ASCO 2025
Luis G Paz-Ares MD PhD discdusses the addition of lurbinectedin as maintenance therapy for extensive stage small cell lung cancer (SCLC)

Frank A Sinicrope MD: Stage 3 Colon Cancer with Deficient Mismatch Repair: Big Gains from Atezolizumab Added to Standard Chemotherapy
An interview with: Frank A Sinicrope, MD, Medical Oncologist, Mayo Clinic, Rochester, Minnesota. CHICAGO —Big gains in survival have been reported among patients with stage three, node-positive colon
